Skip to main
GRI
GRI logo

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc. presents an attractive investment opportunity due to its promising clinical-stage programs, particularly with GRI-0621 and GRI-0803, targeting serious immune-related disorders. The company's valuation analysis indicates a significant upside potential, as evidenced by a lowered price target of $40, reflecting robust net present value despite acknowledging inherent risks in biotech investing. Furthermore, the increasing incidence of idiopathic pulmonary fibrosis (IPF), with over 40,000 new cases diagnosed annually, highlights a growing market need for effective therapies, further supporting a favorable outlook for GRI Bio's product candidates.

Bears say

GRI Bio Inc reported a net loss of $3.9 million, translating to an earnings per share (EPS) of $(7.72), which significantly exceeded both the company's estimates of $(4.08) and the consensus estimate of $(5.44). The financial report highlights significant balance sheet and liquidity risks, coupled with uncertainties surrounding the success of its product candidates in clinical trials and their ability to gain regulatory approval. Additionally, the company faces challenges related to commercialization, competition, and fluctuating investor sentiment towards biotech stocks, all of which contribute to a negative outlook on its stock performance.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.